| Market Cap | 1.09B | P/E | 6.41 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | 122.4M | Forward P/E | 0.19 | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | 190.6M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -16.00% |
| Dividend | N/A | Price/Book | 1.93 | EPS next 5Y | 22.00% | 52W High Chg | -36.00% |
| Recommedations | 2.20 | Quick Ratio | 3.20 | Shares Outstanding | 613.89M | 52W Low Chg | 12.00% |
| Insider Own | 31.49% | ROA | 2.35% | Shares Float | 387.62M | Beta | 0.45 |
| Inst Own | 70.96% | ROE | 25.40% | Shares Shorted/Prior | -/- | Price | 1.77 |
| Gross Margin | 53.20% | Profit Margin | 64.22% | Avg. Volume | 1,773 | Target Price | 173.40 |
| Oper. Margin | 11.81% | Earnings Date | - | Volume | 334 | Change | 0.00% |
Vectura Group plc engages in the design, development, and supply of pharmaceutical products related to inhalation. Its products include flutiform, flutiform K-haler, Ultibro Breezhaler, Seebri Breezhaler, Enerzair Breezhaler, AirFluSal Forspiro, Airbufo Forspiro, Fluticasone Propionate and Salmeterol, Incruse Ellipta, Anoro Ellipta, Trelegy Ellipta, Relvar/Breo Ellipta, and Breelib. The company also provides formulation, process development and tech transfer, pharmaceutical analysis, product manufacturing, and device platforms services, as well as regulatory affairs, device vigilance, and pharmacovigilance services. In addition, it is developing VR315 (US), a generic Advair. Further, the company offers dry powder and pressurized metered dose inhalers, as well as vibrating mesh and jet nebulizers. Vectura Group plc was incorporated in 1997 and is based in Chippenham, the United Kingdom.